NCT07486713 2026-03-20
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Rigel Pharmaceuticals
Phase 4 Recruiting
Rigel Pharmaceuticals
GT Medical Technologies, Inc.
GT Medical Technologies, Inc.
Medical College of Wisconsin